Skip to main content

Advertisement

SpringerLink
Log in

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Yeo W, Johnoson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.

    Article  PubMed  CAS  Google Scholar 

  2. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–6.

    Article  PubMed  Google Scholar 

  3. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547–53.

    Article  PubMed  CAS  Google Scholar 

  4. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116:115–21.

    PubMed  CAS  Google Scholar 

  5. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013–7.

    Article  PubMed  CAS  Google Scholar 

  6. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.

    Article  PubMed  CAS  Google Scholar 

  7. Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16.

    Article  PubMed  Google Scholar 

  8. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.

    Article  PubMed  CAS  Google Scholar 

  9. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.

    Article  PubMed  CAS  Google Scholar 

  10. Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian workshop. Dig Liver Dis. 2011;43:259–65.

    Article  PubMed  Google Scholar 

  11. Marignani M, Marzano A. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen–negative/antibody to hepatitis B core antigen–positive patients receiving chemotherapy for onco-hematologic malignancies. J Clin Oncol. 2010;29:e210.

    Article  Google Scholar 

  12. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. 2010;28:5097–100.

    Article  PubMed  CAS  Google Scholar 

  13. Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin’s lymphoma. The International non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  14. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–7.

    Article  PubMed  CAS  Google Scholar 

  15. Coppola N, Masiello A, Tonziello G, Pisapia R, Pisaturo M, Sagnelli C, et al. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat. 2010;17:493–500.

    PubMed  CAS  Google Scholar 

  16. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.

    Article  PubMed  CAS  Google Scholar 

  17. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2009;38:58–61.

    Article  PubMed  Google Scholar 

  18. Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5.

    Article  PubMed  CAS  Google Scholar 

  19. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–9.

    Article  PubMed  Google Scholar 

  20. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243–50.

    Article  PubMed  CAS  Google Scholar 

  21. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    Article  PubMed  CAS  Google Scholar 

  22. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.

    Article  Google Scholar 

  23. Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: detection and significance. Dig Dis. 2010;28:116–25.

    Article  PubMed  Google Scholar 

  24. Ceccarelli L, Salpini R, Sarmati L, Svicher V, Bertoli A, Sordillo P, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65(2):180–3.

    Google Scholar 

  25. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007;85:16–23.

    Article  PubMed  CAS  Google Scholar 

  26. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7.

    Article  PubMed  CAS  Google Scholar 

  27. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol. 2008;83:673–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from Regione Campania “Progetti per il miglioramento della qualità dell’assistenza, diagnosi e terapia del paziente affetto da AIDS nei settori: immunologia, coinfezioni, informazione e prevenzione”, 2008, and in part by a grant from Ricerca Ateneo 2008, The Second University of Naples, Italy.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Via L. Armanni 5, 80131, Naples, Italy

    Gilda Tonziello, Marintonietta Pisaturo, Giuseppe Pasquale, Evangelista Sagnelli & Nicola Coppola

  2. Haematology Unit, Second University of Naples, Naples, Italy

    Antonello Sica, Maria Giovanna Ferrara & Salvatore Guastafierro

  3. Department of Clinical and Experimental Medicine and Surgery “F Magrassi e A Lanzara”, Second University of Naples, Via Pansini 5, 80131, Naples, Italy

    Caterina Sagnelli

Authors
  1. Gilda Tonziello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marintonietta Pisaturo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonello Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Giovanna Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Caterina Sagnelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppe Pasquale
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evangelista Sagnelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Salvatore Guastafierro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nicola Coppola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evangelista Sagnelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonziello, G., Pisaturo, M., Sica, A. et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 41, 225–229 (2013). https://doi.org/10.1007/s15010-012-0305-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-012-0305-y

Keywords

Search

Navigation